이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Commercial Prebiotic Supplement Study

2017년 10월 24일 업데이트: University of Aberdeen

Effect of Prebiotic in Type 2 Diabetes (Diabetes and Health Study)

Previous work in 2015/16 has identified changes in the gut microbiota with prebiotic (Molkosan®) supplement. It report significant changes in metabolic health bio-markers and faecal SCFA profile in 18 health adult subjects consuming 20 ml of product twice a day. Improvement in fasting metabolic parameters was observed flowing the intervention period. A reduction on Total Cholesterol, Glucose, Triglycerides and Insulin was observed.

In this study, a lower dose (20ml/d) in subjects with type 2 diabetes will be examed, over an extended period of time (12 week period) to match the profile of the intended consumer and provide preliminary data to support a larger multi-centre trial.

연구 개요

상태

알려지지 않은

상세 설명

The study will be conducted in males and females with type 2 diabetes managed by diet and lifestyle alone.

The participants who meet the inclusion and exclusion criteria of the study will attend a screening visit where they will complete a medical screening and sign the consent form for participation in the study. Participates will visit the Human Nutrition Unit at the Rowett Institute to provide samples at week 0 (baseline), week 6 and week 12.

Participants' height, weight, and blood pressure will also be recorded. The investigators will measure HbA1c by a finger prick blood sample to confirm whether participants are a prediabetic or type 2 diabetic subjects. A 3-day weighed intake food diary will be completed during the initial washout period (minimum of 7 days) of the study in order to note their normal eating habits. No probiotic or prebiotics to be consumed during washout period and study period.

During the study periods, participants will take 20ml of prebiotic daily over the 12 consecutive weeks.

For the study visits, each participant will undergo, on two separated occasions, an OGTT, with and without the product at week 0 (to assess acute effects, prior to chronic ingestion) and at week 12 (to assess acute effects after chronic ingestion). The two OGTTs (with and without test product) will be separated by a period of 48 hr. Thus, each participant will have four OGTTs during the study. To minimise systematic errors, one half of the participants will start with the test product OGTT and the other half will start without product OGTT. The starting order will be determined randomly. Six blood samples will be collected during the course of 3 hours (0, 30, 60, 90,120 and 180 min) using a cannulation after consuming 75 g of Polycal liquid (glucose load). Together with OGTT, breath samples will be taken every 30 min for measuring hydrogen and methane.

Only one fasted blood sample will be taken at week 6 (OGTT will not be performed at week 6).

Finger prick blood sample will be taken at week 12 to monitor for changes in HbA1c levels after prebiotic supplement.

Plasma samples will be collected from all blood samples from OGTTs and week 6 blood sample. Plasma glucose and lipid profiles (total cholesterol, HDL, LDL and triglycerides) will be measured by KONI analysis at the University of Aberdeen. Insulin will be measured by ELISA by researchers. All the plasma samples which are taken before and after taking the prebiotic supplement also be analysed for GLP-1, GIP, c-peptide and glucagon analysis by luminex assay.

GLP-1 and GIP are incretins which are produced in the intestinal mucosa and are normally secreted when food is eaten in order to reduce glycaemic exclusion by causing an increase in insulin secretion. These incretins are involved in the early stage of the insulin secretory response however the plasma insulin response is also influenced by hepatic insulin extraction which GLP-1 and GIP measurement cannot determine, therefore to optimise this, C-peptide will be also measured in this study.

All the data will be compared before and after supplementation and values are presented by means ± standard deviations.

From the faecal samples, the SCFA content of the samples to be determined by capillary gas chromatography. SCFA to be quantified against authentic standards of acetate, propionate, butyrate, valerate and the branched chain fatty acids iso-butyrate and iso-valerate. The lower limit for reliable detection of each product is 0.2 mM. DNA to be extracted at University of Aberdeen using the FastDNA spin kit for faeces following the manufacturer's instructions and quantitative PCR (qPCR). Samples and standards are prepared in 96 well plate format, enabling the use of a multichannel pipettes for setting up the running plate. PCR primer sets and amplification conditions are as described in previous studies.

The complete dataset will be analysed and values will be presented as a mean value and standard deviation. Then the baseline value and the value after supplementation (at 6 and 12 weeks) will be compared. Statistically significantly differences will be calculated by statistician with power calculate.

연구 유형

중재적

등록 (예상)

12

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Aberdeen, 영국, AB25 2ZD
        • 모병
        • The Rowett Institute, Human Nutrition Unit
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Impaired glucose tolerance (IGT, identified by HbA1c) or type 2 diabetes (lifestyle management; identified by HbA1c) age 18-65, with BMI 18-40 kg m-2, measured at screening visit.

Exclusion Criteria:

  • Type 1 Diabetes, Severe gastrointestinal disorders (IBD), Kidney disease, Thromboembolic or coagulation disease, Hepatic disease, Alcohol or any other substance abuse, Eating disorders, Unregulated thyroid disease, Antibiotic use within the last 3 months, including proscribed and prescribed use. Current probiotic use or prebiotic use. Medication for glucose regulation. Female with breast feeding.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 다른
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 12 type 2 diabetes patients
Long-term dietary (12 weeks) intervention of 20ml of prebiotic per day
12 volunteers will take 20ml of prebiotic per day for 12 weeks

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change of oral glucose tolerance test (OGTT)
기간: At baseline and 12 weeks prebiotic consumption
Six blood samples will be collected during the course of 3 hours (0, 30, 60, 90,120 and 180 min) using a cannulation after consuming 75 g of Polycal liquid (glucose load). Plasma glucose level will be measured by KONI analysis and
At baseline and 12 weeks prebiotic consumption

2차 결과 측정

결과 측정
측정값 설명
기간
Change of insulin levels
기간: At baseline, 6 weeks and 12 weeks prebiotic consumption
Six blood samples will be collected during the course of 3 hours (0, 30, 60, 90,120 and 180 min) using a cannulation after consuming 75 g of Polycal liquid (glucose load). insulin level will be measured by luminex assay.
At baseline, 6 weeks and 12 weeks prebiotic consumption
HbA1c measured by Alere Afinion™ AS100 Analyzer
기간: At baseline and 12 weeks prebiotic consumption

The term HbA1c refers to glycated haemoglobin. It develops when haemoglobin, a protein within red blood cells that carries oxygen throughout the body. By measuring glycated haemoglobin (HbA1c) can indicate blood sugar levels.

Finger prick method will be introduced to collect the small amount of blood samples into the Alere Afinion™ AS100 Analyzer cartridge. Insert cartridge to the machine to read the data. Inclusion criteria will be the levels above 6 % (42mmol/mol). We will also measure HbA1c at 12 week to monitor for changes.

At baseline and 12 weeks prebiotic consumption
Change of BMI (kg/m^2) measurement
기간: At baseline and 12 weeks prebiotic consumption
Weight or Body Mass is defined as the quantity of matter in the body, measured by weight (kg) i.e. the force that matter exerts under standard gravitational effect. Height (m) will be recorded for conjunction with weight measurements to calculate Body Mass Index (BMI) values.
At baseline and 12 weeks prebiotic consumption
Change of Total Cholesterol levels
기간: At baseline, 6 weeks and 12 weeks prebiotic consumption
Total cholesterol (HDL and LDL -Cholesterols) will be measured by KONI analysis at University of Aberdeen. Separately measured HDL- and LDL-cholesterols levels will be combined for total cholesterol levels.
At baseline, 6 weeks and 12 weeks prebiotic consumption
Change of GLP-1 levels
기간: At baseline, 6 weeks and 12 weeks prebiotic consumption
The incretin hormones, glucagon-like peptide-1 (GLP-1) secretion, contributes to glucose intolerance. GLP-1 levels will be measured by luminex assay.
At baseline, 6 weeks and 12 weeks prebiotic consumption
Change of GIP levels
기간: At baseline, 6 weeks and 12 weeks prebiotic consumption
Glucose-dependent insulinotropic polypeptide (GIP) is potentiate the insulin response to nutrients. Insulinotropic capacity of GIP is markedly diminished in type 2 diabetes. Incretin hormone GIP will be measured by luminex assay.
At baseline, 6 weeks and 12 weeks prebiotic consumption
Change of triglyceride levels
기간: At baseline, 6 weeks and 12 weeks prebiotic consumption
Triglyceride levels will be measured for identifying the lipid profiles. Triglyceride will be measured by KONI analysis.
At baseline, 6 weeks and 12 weeks prebiotic consumption
Change of C-peptide levels
기간: At baseline, 6 weeks and 12 weeks prebiotic consumption
C-peptide are involved to hepatic insulin extraction. C-peptide levels are measured by luminex assay.
At baseline, 6 weeks and 12 weeks prebiotic consumption
Change of glucagon levels
기간: At baseline, 6 weeks and 12 weeks prebiotic consumption
Glucagon levels will be measured by luminex assay.
At baseline, 6 weeks and 12 weeks prebiotic consumption
Change of fermentation markers
기간: At baseline and 12 weeks prebiotic consumption
Breath samples will be measured hydrogen and methane levels
At baseline and 12 weeks prebiotic consumption

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Alexandra M Johnstone, PhD, University of Aberdeen, The Rowett Institute

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2017년 5월 10일

기본 완료 (예상)

2018년 6월 30일

연구 완료 (예상)

2018년 8월 1일

연구 등록 날짜

최초 제출

2017년 2월 8일

QC 기준을 충족하는 최초 제출

2017년 5월 4일

처음 게시됨 (실제)

2017년 5월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2017년 10월 25일

QC 기준을 충족하는 마지막 업데이트 제출

2017년 10월 24일

마지막으로 확인됨

2017년 2월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • Study 805

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

제2형 당뇨병에 대한 임상 시험

  • Postgraduate Institute of Medical Education and...
    완전한
    Type 2 HRS에서 Terlipressin과 Noradrenaline의 안전성과 효능 및 예측반응인자
    인도
3
구독하다